First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment

Pituitary. 2012 Dec;15 Suppl 1:S57-60.
Baldari S, Ferraù F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F, Cannavò S.
Pituitary. 2012 Dec;15 Suppl 1:S57-60.
Relazione sull'efficacia e la sicurezza della terapia del recettore del peptide radionuclide (PRRT) con 111-Indium-DTPA-octreotide in un paziente con aggressivo prolattinoma gigante resistente al trattamento convenzionale.
111-Indium-DTPA-octreotide/prolattinoma gigante.

In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects 2 were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled
somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.